Ryan H. Saadi Sells 1,438,206 Shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Stock

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) CEO Ryan H. Saadi sold 1,438,206 shares of Tevogen Bio stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $1.23, for a total value of $1,768,993.38. Following the completion of the sale, the chief executive officer now directly owns 116,814,453 shares in the company, valued at $143,681,777.19. This represents a 1.22% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Tevogen Bio Stock Up 12.7%

NASDAQ:TVGN opened at $1.24 on Wednesday. The stock’s 50-day simple moving average is $1.12 and its 200 day simple moving average is $1.20. Tevogen Bio Holdings Inc. has a 52-week low of $0.26 and a 52-week high of $3.09.

Hedge Funds Weigh In On Tevogen Bio

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Barclays PLC grew its holdings in Tevogen Bio by 39.2% during the fourth quarter. Barclays PLC now owns 45,600 shares of the company’s stock worth $48,000 after purchasing an additional 12,847 shares during the period. Northern Trust Corp grew its holdings in Tevogen Bio by 13.0% during the fourth quarter. Northern Trust Corp now owns 118,415 shares of the company’s stock worth $122,000 after purchasing an additional 13,595 shares during the period. JPMorgan Chase & Co. grew its holdings in Tevogen Bio by 74.2% during the fourth quarter. JPMorgan Chase & Co. now owns 39,207 shares of the company’s stock worth $40,000 after purchasing an additional 16,695 shares during the period. XTX Topco Ltd bought a new position in Tevogen Bio during the fourth quarter worth about $55,000. Finally, Nuveen LLC bought a new position in Tevogen Bio during the first quarter worth about $97,000.

Wall Street Analyst Weigh In

Separately, D. Boral Capital reaffirmed a “buy” rating and issued a $10.00 target price on shares of Tevogen Bio in a research report on Tuesday.

Tevogen Bio Company Profile

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.